Site Map
Research Article
Role of Glucocorticoids and Stress in Pathogeny of Diabetes Mellitus and Related Disorders
Viktor Ivanovitch Goudochnikov*
Council of International Society for DOHaD, Santa Maria, Rio Grande do Sul, Brazil

ABSTRACT
Presented work aimed at preparing literature review that could describe the contribution of Glucocorticoids (GC) and stress to pathogeny of diabetes mellitus and related disorders: Metabolic syndrome and obesity. This review includes the following topics: Effects of GC and stress on glucose metabolism, the role of GC and stress in pathogenetic mechanisms of clinical and experimental diabetes, the importance of catecholamines and other stress hormones in mechanisms of hypo and hyperglycemia, interactions of GC with high-fat diet, contribution of GC to comorbidity of metabolic and neuropsychiatric disorders, metabolic consequences of prolonged GC treatment, the role of GC in programming/imprinting phenomena, the importance of stress proteins in pathogeny of metabolic disorders and modes of counteracting stress and GC in diabetes and related diseases. The conclusion is made about the necessity of more detailed evaluation of the effects of hormones having antistress properties, as applied to metabolic disorders.
Keywords: Diabetes mellitus; Glucocorticoids; Metabolic syndrome; Obesity; Stress

Abbreviations
BDNF: Brain Derived Neurotrophic Factor
DHEA: Dehydroepiandrosterone
DOHaD: Developmental Origins of Health and Disease
DST: Dexamethasone Suppression Test
GC: Glucocorticoids
HPA: Hypothalamo Pituitary Adrenal (axis)
HSP: Heat Shock Proteins
iHSP70: Intracellular Hsp70
eHSP70: Extracellular HSP70
eHSP72: Extracellular HSP72
PEPCK: Phosphoenolpyruvate Carboxykinase
PPAR-alpha: Peroxysome Proliferator-Activated Receptor, Type Alpha
PPAR-gamma: Peroxysome Proliferator-Activated Receptor, Type Gamma
SAMS: Sympatho Adrenomedullary System
11beta-HSD1: 11beta-Hydroxysteroid Dehydrogenase Type 1
Introduction
Earlier we have briefly discussed the role of Glucocorticoids (GC) in mechanisms of aging and age-related diseases [1,2]. During such discussion it became clear that it is necessary to describe in more details the role of GC and stress in pathogeny of various diseases. Therefore, the presented work aimed at preparing literature review about the contribution of GC and stress to pathogeny of diabetes mellitus and related disorders, especially metabolic syndrome and obesity. Our choice of GC from the whole spectrum of stress hormones was justified, on one hand, by central positions occupied by GC in metabolic bioregulation and on the other hand, by the broad use of GC in various subfields of medicine as pharmacotherapeutic preparations, mainly with anti-inflammatory and immunosuppressive action. Therefore, it is necessary to consider possible diabetogenic GC action on patients with non-endocrine disorders.
Materials and Methods
For preparing bibliographic review we localized in various commercial databases and public domain of internet the evidence on the role of stress and GC in pathogenetic mechanisms of diabetes mellitus, metabolic syndrome and obesity during the last decades and predominantly in English language, using the key words indicated. Thereafter all the data obtained were sorted according to their degree of importance and reasoning, separating the discussion on clinical and experimental diabetes, metabolic syndrome and obesity, influence of high-fat diet, hypo- and hyperglycemia, finalizing with more complex topics on comorbidity with some neuropsychiatric disorders, the role of heat shock proteins and programming/imprinting phenomena and possible modes of counteracting stress and excessive GC action in diabetic patients.
Two types of stress as related to stress hormones and proteins
At present two main types of stress are considered: The physiologic and cell stress. The physiologic stress is systemic one and realized by means of hormones belonging to Hypothalamic Pituitary Adrenal (HPA) axis and Sympatho Adrenomedullary System (SAMS), first of all GC and catecholamines. On the other hand, cell stress is more localized one and effectuated by means of stress proteins, first of all Heat Shock Proteins (HSP) and metallothioneins. In this article we shall focus mainly on GC and HSP, although other stress hormones and proteins may be also important.
Effects of glucocorticoids and stress on parameters of glucose metabolism
At present GC are considered as functional insulin antagonists [3]. In fact, on systemic level these hormones cause insulin resistance and impaired glucose tolerance, increased gluconeogenesis and decreased glucose transport in targets organs for insulin [4,5]. Correspondingly, GC enhance glucose production in the liver and diminish its consumption in peripheral tissues [6]. These GC properties were confirmed in studies on healthy human volunteers and in experimental models of laboratory animals.
On the other hand, various stress types can increase the risk of diabetes in humans and animals. Really, chronic psychosocial stress in job place doubled the risk of type 2 diabetes in middle-aged women [7]. In experiments on laboratory animals restraint stress caused diabetes after partial resection of the pancreas [6].
The following section will discuss how stress or GC are associated with clinical diabetes and related disorders.
Role of glucocorticoids and stress in pathogenetic mechanisms of clinical diabetes, metabolic syndrome and obesity
First of all, subclinical hypercortisolism is more frequent in patients with type 2 diabetes, especially in the presence of diabetic complications [8]. Besides, stressor events of everyday life are able to increase the risk of diabetes, whereas surgical stress impairs glycemic control [6,9].
The increase in cortisol levels in blood may be responsible for the decrease in wound healing rate in diabetic patients [10]. In such patients the subjective perceptions of stress are enhanced, and coping processes are decreased [11].
In patients with metabolic syndrome urinary excretion of metabolites of cortisol and catecholamines is increased [12]. Besides, in such patients cortisol concentration in blood correlated to the degree of insulin resistance [13]. In obesity urinary excretion of cortisol metabolites is also increased [14]. Moreover, in obesity the relation between adrenal size and the risk of type 2 diabetes was revealed [15].
Special position is occupied by polycystic ovary syndrome that shares many features with metabolic disorders. In patients with such syndrome the enhanced reaction of hyperglycemia to dexamethasone administration was observed [16].
The role of catecholamines and other stress hormones in mechanisms of hypo and hyperglycemia, as well as other metabolic disorders
It is well known that hypoglycemia represents one of the most powerful stressors, being able to stimulate the secretion of GC, catecholamines, glucagon, vasopressin and other stress hormones. It was established also that repeated iatrogenic hypoglycemia provokes the disturbances of SAMS that result consequently in impaired capacity to recognize the foregoing hypoglycemia by patients [17].
On the other hand, acute stress-induced hyperglycemia may indicate enhanced risk of mortality and impaired functional recovery in non-diabetic patients [18]. Besides, prolonged hyperglycemia caused by chronic stress in rats can be considered as manifestation of allostatic load [19].
It is suggested that nearly all the components of metabolic syndrome are related to disturbances in SAMS [20], whereas diabetes of type 1 represents a state of excessive activity of this system [21].
Role of glucocorticoids and stress in pathogeny of experimental diabetes and metabolic disturbances related to high-fat diet
In rats and mice with experimental diabetes the levels of GC and adrenaline in blood are increased, and the reaction to restraint stress is enhanced [6,11]. Experimental diabetes potentiated adverse influence of chronic stress on hippocampus [22,23]. Hippocampal disturbances in animals with experimental diabetes were prevented by GC antagonist RU-486 [24].
Chronic moderate stress in mice with experimental diabetes leads to higher degree of hyperglycemia and to decrease in survival [25]. Probably, in diabetes GC have lost their homeostatic function and become the brain-damaging agents [26].
The most significant results were observed in the cases of combined influence of GC and high-fat diet. In fact, such combination provoked really dramatic enhancement of glucose and lipid levels in blood, as well as of insulin resistance [27]. Combined action of exogenous corticosterone and high-fat diet resulted in unusually rapid development of phenotype of metabolic syndrome or type 2 diabetes [28].
The question therefore emerges: How these data are applied to real clinical situations? As a matter of fact, GC possess orexygenic action enhancing appetite, especially as referred to highly caloric food stuffs, rich in carbohydrates and lipids [29]. In relation to this, it is very interesting that high cortisol level in blood of type 2 diabetic patients correlates to predominant choice of such products [30]. On the other hand, it was shown that high-fat diet consumption activates HPA axis [27] that results in creation of vicious cycle of positive feed forward influences. However, it is important to note here that the effects of GC on metabolism in peripheral organs should be considered also, besides their central influence on appetite.
In addition to important role of the diet, aging process in itself may be responsible for interactions between GC, stress and metabolic disturbances. Really, aging is accompanied by decreased efficacy of GC negative feedback mechanism and HPA axis hyperactivity. As a result, in elderly patients with chronic diseases the progressive increase of cortisol levels in blood is observed, especially in the evening [1]. The important role in such disturbances is played by atrophic hippocampal changes that can favor the comorbidities with neuropsychiatric disorders.
Role of glucocorticoids in comorbidities of metabolic and neuropsychiatric disorders
Stress hormones appear to occupy central positions in the pathogeny of both metabolic syndrome or obesity and depression [31,32]. In diabetic patients the psychic depression is observed more frequently, with common pathogenic factors of such comorbidity being enhanced secretion of GC, catecholamines, glucagon and other stress hormones, as well as decreases in neurogenesis and in the level of Brain Derived Neurotrophic Factor BDNF [33]. The consequence of chronic hyperglycemia is accelerated brain aging. The risk of comorbid depression is enhanced by diabetes as chronic metabolic stressor; in both cases elevated cortisol level in blood and disturbances of its circadian rhythm and in the results of the test of suppressing cortisol secretion by Dexamethasone (DST) give the evidence of impaired negative feedback associated with hippocampal atrophy and worsened cognitive processes and memory. Moreover, patients with diabetes demonstrate more severe progressing of comorbid depression and 10 fold higher risk of suicide [34].
Approximately 25-60% of patients with bipolar disorder show the symptoms of metabolic syndrome. The enhanced blood levels of catecholamines and GC in such patients already in early stages of disease are considered to be the manifestation of allostatic load [35]. In schizophrenia it should be considered also that elevated activity of SAMS and HPA axis can provoke diabetogenic influence [36].
The following section will discuss the actions of exogenous GC used as pharmacotherapeutic agents.
Metabolic consequences of pharmacotherapy with exogenous glucocorticoids
The diabetes is considered as quite common complication of chronic influence of excessive GC and can be the risk factor of enhanced mortality. More than a half of patients with kidney disease demonstrate impaired tolerance to glucose and diabetes already after 10 weeks of treatment with prednisone, and higher GC dose results in more probable necessity to prescribe hypoglycemic peroral drugs [37]. Prolonged pharmacotherapy with GC is responsible for 2% of diabetes cases in ambulatory patients [38].
About 35% of patients with rheumatoid arthritis that use GC during prolonged period of time, demonstrate disturbances of glucose metabolism [39]. As some authors note, it can happen that using GC, the patients may “exchange” one disease (for example, bronchial asthma) to another (metabolic syndrome or diabetes) [40].
Therefore, it is critically important for physicians prescribing GC even in small doses to consider the risk of iatrogenic metabolic disorders [39]. However, only in transplantology there exist recommendations for regular checking blood glucose levels in the cases of prolonged GC treatment, but unfortunately, these recommendations do not consider that frequently GC do not alter basal glucose levels in blood [37].
Special position is occupied by pharmacotherapy with exogenous GC in perinatal period of development. In this sense, it was shown that administration of synthetic GC to premature infants leads to their decreased sensitivity to insulin [41]. These data are related to the evidence of important role of GC in phenomena of programming/imprinting.
Role of glucocorticoids in phenomena of programming/imprinting of metabolic disorders
In the frame of concept of Developmental Origins of Health and Disease (DOHaD) it was shown that dexamethasone administration to pregnant rats resulted in impaired glucose tolerance and insulin resistance in the offspring already in adult state, as well as in elevated expression of GC receptors and key enzyme of gluconeogenesis PEPCK in the liver [42]. The stress of pregnant rats also caused impaired glucose tolerance in the offspring already in aging period [43].
In general, the data obtained in different animal species show that the action of excessive GC in perinatal period of development provokes the progressing of metabolic disorders in later life. In this sense, it is interesting that in the individuals with low birth weight, higher activity of HPA axis is observed already in adult state, what can be responsible for the development of visceral obesity and metabolic syndrome [44,45].
Just recently we tried to attract the attention to insufficient description of cell stress mechanisms in the endocrinological literature [46]. In fact, contrary to hormonal mechanisms of so called physiologic stress, the role of cell stress in pathogeny of diabetes and related disorders is poorly studied yet.
The importance of stress proteins in pathogeny of metabolic disorders
It was shown that intracellular levels of HSP are low in clinical and experimental diabetes and in the cases of insulin resistance. This situation can enhance the vulnerability of diabetic patients to lesions of cells and tissues [47].
Relatively recently it was discovered that there exists non-classic, exosomal mechanism of release for one of principal components of the family of stress proteins-HSP70 from the cells to extracellular fluid. Besides, if intracellular HSP70 (iHSP70), for example, in leukocytes of peripheral blood, has anti-inflammatory action by means of inactivation of transcription factor NF-kappaB, in contrast, extracellular HSP70 (eHSP70) characterizes enhanced activity of immune system and inflammatory processes, therefore the relation eHSP70/iHSP70 can be used as indicator showing the tendency to generalized inflammation [48].
It seems that in diabetes the elevated relation eHSP70/iHSP70 occurs, what explains the vulnerability of diabetic patients to inflammatory complications. Moreover, it was shown that hypoglycemia, i.e., well-known stressor, leads to enhanced level of eHSP72 that appears to serve as danger signal to switching-on the mechanisms of defense against immune and metabolic disorders [49].
Undoubtedly, these interesting data can lead to the necessity of re-evaluating many established concepts on the role of GC and stress in mechanisms of metabolic disorders. However, as already it was noted in our previous work [46], the obstacle on the way of such re-evaluation may be insufficiently studied interactions between the proteins and hormones of stress.
Finally, based on above mentioned facts, let’s discuss how counteracting stress and excessive GC can help in the treatment of patients with diabetes and related disorders.
Modes of counteracting stress and glucocorticoids as possible means of treatment of metabolic disorders
One of such means may be the diet with low contents of carbohydrates and fat, that can prevent activation of HPA axis in patients with diabetes, as can be deduced from evidence mentioned above. However, in order to not provoke the undesirable disbalance of macronutrients (with excessive protein content in the diet), perhaps, the total caloric restriction is preferable in these cases. Another non-drug mode may be moderate but regular physical activity that in contrast to acute physical exercise is able to paradoxically decrease the secretion of stress hormones, as well as to diminish the relation eHSP70/iHSP70 [47,50]. Warm bath appears to do partially the same [47]. Behavioral training of relaxation may improve glucose tolerance and decrease the secretion of cortisol and catecholamines in hospitalized patients [6].
What for drugs, insulin appears to be the drug of choice for treating GC-induced hyperglycemia [51]. In addition, antidiabetic preparations, agonists of PPAR-gamma and clofibrate-agonist of PPAR-alpha are able to inhibit the enzyme 11beta-HSD1 that reactivates cortisol from inactive cortisone, what can promote the decrease in local cortisol production in adipose tissue [44]. In this sense, it was shown that inhibition of 11beta-HSD1 activity by carbenoxolone improves cognitive functions and memory both in patients with type 2 diabetes and in healthy elderly persons [52], whereas neuro active steroid DHEA decreases the activity of this enzyme in adipocytes [53]. It should be underlined that in general, novel inhibitors of 11beta-HSD1 represent promising tools of treating diabetes, obesity and other metabolic disorders [54,55].
On the other hand, antidiabetic preparation glyburide can enhance insulin secretion by means of antagonism on the level of alpha2-adrenergic receptors [6]. In this sense, it was noted long time ago that the importance of stress-limiting systems consists of the blockade of adrenergic effects of stress [56]. The modes of enhancement of such stress-limiting systems are the use of benzodiazepine preparations, e.g., Alprazolam [6], and the employment of antioxidants [57], considering also the capacity of excessive GC to provoke oxidative stress [58]. Nevertheless, it should be noted here that the use of various drugs like adrenergic blockers, benzodiazepines or antioxidants for counteracting stress or GC effects is only beginning to be considered, and a lot of investigative efforts are needed yet for clarifying this emergent topic.
Conclusion
Recently we discussed the modes of counteracting stress and GC in early ontogeny [59] and in aging [60,61]. Such modes include melatonin and neuroactive steroids, such as DHEA, as well as oxytocin, insulin-like growth factors and somatolactogens. However, growth hormone is considered to be the stress hormone and can induce insulin resistance [62]. It means that in future studies it will be important to discuss in more detail the action of such hormones, as referred to metabolic disorders.
On the other hand, hormetic phenomena should be taken into account, considering that mild stress may be beneficial, especially in aging [63]. However, future studies should establish more clearly the thresholds separating acute and chronic, as well as mild, moderate and intense stress types.
And finally, the role of epigenetic mechanisms in the effects of GC and stress during experimental and clinical diabetes should be investigated more thoroughly. At present there exist only scarce data, e.g., on methylation of promoters in the gene of 11beta-HSD1 [64], although, as related to DOHaD concept and aging, the promising epigenetic perspectives involving GC and stress are already emerging [65,66].
Acknowledgement
The author is grateful to unknown reviewers for valuable suggestions that allowed to greatly improve the final version of this manuscript.
Conflict of Interest
The author affirms that conflict of interests related to this work does not exist.

References
  1. Goudochnikov VI (2011) The role of glucocorticoids in aging and age-related pharmacotherapy. Adv Gerontol 24: 48-53.
  2. Goudochnikov VI (2010) Stress mediators in pathogeny of age-related diseases. In: 10th ISMA-BR Congress of Stress. Porto Alegre, Brazil.
  3. Strack AM, Sebastian RJ, Schwartz MW, Dallman MF (1995) Glucocorticoids and insulin: Reciprocal signals for energy balance. Am J Physiol 268: 142-149.
  4. Tappy L, Randin D, Vollenweider P, Vollenweider L, Paquot N, et al. (1994) Mechanisms of dexamethasone-induced insulin resistance in healthy humans. J Clin Endocrinol Metab 79: 1063-1069.
  5. Andrews RC, Walker BR (1999) Glucocorticoids and insulin resistance: Old hormones, new targets. Clin Sci (Lond) 96: 513-523.
  6. Surwit RS, Schneider MS (1993) Role of stress in the etiology and treatment of diabetes mellitus. Psychosom Med 55: 380-393.
  7. Heraclides A, Chandola T, Witte DR, Brunner EJ (2009) Psychosocial stress at work doubles the risk of type 2 diabetes in middle-aged women: Evidence from the Whitehall II study. Diabetes Care 32: 2230-2235.
  8. Chiodini I, Adda G, Scillitani A, Coletti F, Morelli V, et al. (2007) Cortisol secretion in patients with type 2 diabetes: Relationship with chronic complications. Diabetes Care 30: 83-88.
  9. Lloyd C, Smith J, Weinger K (2005) Stress and diabetes: A review of the links. Diabetes Spectrum 18: 121-127.
  10. Bitar MS (1998) Glucocorticoid dynamics and impaired wound healing in diabetes mellitus. Am J Pathol 152: 547-554.
  11. Rowland NE, Bellush LL (1989) Diabetes mellitus: Stress, neurochemistry and behavior. Neurosci Biobehav Rev 13: 199-206.
  12. Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, et al. (2002) Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: Nested case-control study. Circulation 106: 2659-2665.
  13. Wang M (2005) The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Nutr Metab (Lond) 2: 3.
  14. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, et al. (2001) Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86: 1418-1421.
  15. Roberge C, Carpentier AC, Langlois MF, Baillargeon JP, Ardilouze JL, et al. (2007) Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity. Am J Physiol Endocrinol Metab 293: 1465-1478.
  16. Ehrmann DA, Breda E, Corcoran MC, Cavaghan MK, Imperial J, et al. (2004) Impaired beta-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab 287: 241-246.
  17. Cryer PE (2001) Hypoglycemia-associated autonomic failure in diabetes. Am J Physiol 281: 1115-1121.
  18. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC (2001) Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: A systematic overview. Stroke 32: 2426-2432.
  19. Nirupama R, Devaki M, Yajurvedi HN (2012) Chronic stress and carbohydrate metabolism: Persistent changes and slow return to normalcy in male albino rats. Stress 15: 262-271.
  20. Vaccarino V, Bremner JD (2005) Stress response and the metabolic syndrome. Hospital Physician 11.
  21. Mead VP (2004) A new model for understanding the role of environmental factors in the origins of chronic illness: A case study of type 1 diabetes mellitus. Med Hypotheses 63: 1035-1046.
  22. Stranahan AM, Arumugam TV, Cutler RG, Lee K, Egan JM, et al.(2008) Diabetes impairs hippocampal function via glucocorticoid-mediated effects on new and mature neurons. Nat Neurosci 11: 309-317.
  23. Magarinos AM, McEwen BS (2000) Experimental diabetes in rats causes hippocampal dendritic and synaptic reorganization and increased glucocorticoid reactivity to stress. Proc Natl Acad Sci U S A 97: 11056-11061.
  24. Revsin Y, Rekers NV, Louwe MC, Saravia FE, De Nicola AF, et al. (2009) Glucocorticoid receptor blockade normalizes hippocampal alteractions and cognitive impairment in streptozotocin-induced type I diabetes mice. Neuropsychopharmacology 34: 747-758.
  25. Rubinstein MR, Cremaschi GA, Oliveri LM, Gerez EN, Wald MR, et al. (2010) Possible involvement of stress hormones and hyperglycaemia in chronic mild stress-induced impairment of immune functions in diabetic mice. Stress 13: 384-391.
  26. Revsin Y, de Kloet ER (2009) When glucocorticoids change from protective to harmful: Lessons from a type 1 diabetes animal model. Medicina 69: 353-358.
  27. Sivabalan S, Renuka S, Menon VP (2008) Fat feeding potentiates the diabetogenic effect of dexamethasone in Wistar rats. Int Arch Med 1: 7.
  28. Shpilberg Y, Beaudry JL, D’Souza A, Campbell JE, Peckett A, et al. (2012) A rodent model of rapid-onset diabetes induced by glucocorticoids and high-fat feeding. Dis Model Mech 5: 671-680.
  29. Nieuwenhuizen AG, Rutters F (2008) The hypothalamic-pituitary-adrenal axis in the regulation of energy balance. Physiol Behav 94: 169-177.
  30. Duong M, Cohen JI, Convit A (2012) High cortisol levels are associated with low quality food choice in type 2 diabetes. Endocrine 41: 76-81.
  31. Gragnoli C (2014) Hypothesis of the neuroendocrine cortisol pathway gene role in the comorbidity of depression, type 2 diabetes, and metabolic syndrome. Appl Clin Genet 7: 43-53.
  32. Bornstein SR, Schuppenies A, Wong ML, Licinio J (2006) Approaching the shared biology of obesity and depression: The stress axis as the locus of gene-environment interactions. Mol Psychiatry 11: 892-902.
  33. Rustad JK, Musselman DL, Nemeroff CB (2011) The relationship of depression and diabetes: Pathophysiological and treatment implications. Psychoneuroendocrinology 36: 1276-1286.
  34. Reagan LP (2012) Diabetes as a chronic metabolic stressor: Causes, consequences and clinical complications. Exp Neurol 233: 68-78.
  35. Brietzke E, Kapczinski F, Grassi-Oliveira R, Grande I, Vieta E, et al. (2011) Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev Neurother 11: 1017-1028.
  36. Dinan TG (2004) Stress and the genesis of diabetes mellitus in schizophrenia. Br J Psychiatry Suppl 47: 72-75.
  37. Di Dalmazi G, Pagotto U, Pasquali R, Vicennati V (2012) Glucocorticoids and type 2 diabetes: From physiology to pathology. J Nutr Metab 2012: 525093.
  38. Gulliford MC, Charlton J, Latinovic R (2006) Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 29: 2728-2729.
  39. Beaudry JL, Riddel MC (2012) Effects of glucocorticoids and exercise on pancreatic beta-cell function and diabetes development. Diabetes Metab Res Rev 28: 560-573.
  40. Bernal-Mizrachi C, Weng S, Feng C, Finck BN, Knutsen RH, et al. (2003) Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice. Nat Med 9: 1069-1075.
  41. Leipala JA, Raivio KO, Sarnesto A, Panteleon A, Fellman V (2002) Intrauterine growth restriction and postnatal steroid treatment effects on insulin sensitivity in preterm neonates. J Pediatr 141: 472-476.
  42. Nyirenda MJ, Lindsay RS, Kenyon CJ, Burchell A, Seckl JR (1998) Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. J Clin Invest 101: 2174-2181.
  43. Lesage J, Del-Favero F, Leonhardt M, Louvart H, Maccari S, et al. (2004) Prenatal stress induces intrauterine growth restriction and programmes glucose intolerance and feeding behavior disturbances in the aged rat. J Endocrinol 181: 291-296.
  44. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP (2009) Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: A hypothesis. J Clin Endocrinol Metab 94: 2692-2701.
  45. Dzgoeva FK (2015) Intrauterine nutrition: Fetal programming of metabolic syndrome. Obes Metab 12: 10-17.
  46. Goudochnikov VI (2015) Role of stress proteins and hormones in bioregulation of ontogeny. Probl Endocrinol 61: 49-53.
  47. Hooper PL, Hooper JJ (2005) Loss of defense against stress: Diabetes and heat shock proteins. Diabetes Technol Ther 7: 204-208.
  48. Krause M, Heck TG, Bittencourt A, Scomazzon SP, Newsholme P, et al. (2015) The chaperone balance hypothesis: The importance of the extracellular to intracellular HSP70 ratio to inflammation-driven type 2 diabetes, the effect of exercise, and the implications for clinical management. Mediators Inflamm.
  49. Ludwig MS, Minguetti-Camara V, Heck TG, Scomazzon SP, Nunes PR, et al. (2014) Short-term but not long-term hypoglycaemia enhances plasma levels and hepatic expression of HSP72 in insulin-treated rats: An effect associated with IL-6 levels but not with IL-10 or TNF-alpha. Mol Cell Biochem 397: 97-107.
  50. Campbell J, Kiraly MA, Atkinson DJ, D’Souza AM, Vranic M, et al. (2010) Regular exercise prevents the development of hyperglucocorticoidemia via adaptations in the brain and adrenal glands in male Zucker diabetic fatty rats. Am J Physiol Regul Integr Comp Physiol 299: 168-176.
  51. Genolet P, Petite C, Petignat PA (2012) Diabete cortico-induit, une entite frequente sans prise en charge standardisee. Rev Med Suisse 8: 800-805.
  52. Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, et al. (2004) 11beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci U S A 101: 6734-6739.
  53. Apostolova G, Schweizer RA, Balazs Z, Kostadinova RM, Odermatt A (2005) Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue. Am J Physiol Endocrinol Metab 288: 957-964.
  54. Stewart PM, Tomlinson JW (2009) Selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome. Is the target liver, fat, or both? Diabetes 58: 14-15.
  55. Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, et al. et al. (2010) The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB 13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33: 1516-1522.
  56. Meerson FZ (1994) Stress-induced arrhythmic disease of the heart-part I. Clin Cardiol 17: 362-371.
  57. Vegiopoulos A, Herzig S (2007) Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol 275: 43-61.
  58. Prokhorov LY, Goudochnikov VI (2015) Role of glucocorticoids and stress in bioregulation of redox homeostasis in development and aging. Klin Gerontol 21: 101-102.
  59. Goudochnikov VI (2015) Role of hormones in perinatal and early postnatal development: Possible contribution to programming/imprinting phenomena. Russ J Dev Biol 46: 237-245
  60. Prokhrov LY, Goudochnikov VI (2014) Ontogenetic role of melatonin and neuroactive steroids as antistress hormones. Gerontologiya 2: 157-180.
  61. Goudochnikov VI, Prokhorov LY (2014) Ontogenetic role of somatolactogens and related peptides as antistress hormones. Gerontologiya 2: 143-156.
  62. Black PH (2003) The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun 17: 350-364.
  63. Gems D, Partridge L (2008) Stress-response hormesis and aging: “That which does not kill us makes us stronger”. Cell Metab 7: 200-203.
  64. Inder WJ, Obeyesekere VR, Jang C, Saffery R (2012) Evidence for transcript-specific epigenetic regulation of glucocorticoid-stimulated skeletal muscle 11β-hydroxysteroid dehydrogenase-1 activity in type 2 diabetes. Clin Epigenetics 4: 24.
  65. Crudo A, Petropoulos S, Suderman M, Moisiadis VG, Kostaki A, et al. (2013) Effects of antenatal synthetic glucocorticoid on glucocorticoid receptor binding, DNA methylation, and genome-wide mRNA levels in the fetal male hippocampus. Endocrinology 154: 4170-4181.
  66. Hunter RG, Gagnidze K, McEwen BS, Pfaff DW (2015) Stress and the dynamic genome: Steroids, epigenetics, and the transposome. Proc Natl Acad Sci U S A 112: 6828-6833.

Citation:Goudochnikov IV (2018) Role of Glucocorticoids and Stress in Pathogeny of Diabetes Mellitus and Related Disorders. J Diabetes Metab Disord 5: 022.